{"id":"induction-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-90%","effect":"Nausea and vomiting"},{"rate":"20-80%","effect":"Fatigue"},{"rate":"10-70%","effect":"Hair loss"},{"rate":"5-50%","effect":"Infection"},{"rate":"5-40%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This approach is used to reduce tumor size and make it easier to remove or treat. The specific chemotherapy agents used can vary depending on the type and stage of cancer.","oneSentence":"Induction chemotherapy involves administering high-dose chemotherapy to kill cancer cells before a main treatment, such as surgery or radiation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:03.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers, including but not limited to breast cancer, lung cancer, and lymphoma"}]},"trialDetails":[{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07072468","phase":"PHASE2","title":"Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)","status":"RECRUITING","sponsor":"VM Therapeutics LLC","startDate":"2025-12-12","conditions":"Chemotherapy-induced Peripheral Neuropathy, Drug-Induced Nephropathy","enrollment":16},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT03586297","phase":"","title":"Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2017-08-27","conditions":"Triple Negative Breast Cancer","enrollment":49},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT06669299","phase":"NA","title":"Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies","status":"RECRUITING","sponsor":"IRCCS Ospedale San Raffaele","startDate":"2025-06-12","conditions":"Ventricular Tachycardia (VT)","enrollment":51},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT03354741","phase":"NA","title":"Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2019-05-23","conditions":"Children, Chemotherapy-induced Nausea and Vomiting, Malignant Tumor","enrollment":30},{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT07497191","phase":"","title":"AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2026-03-05","conditions":"Breast Cancer, Perimenopause, Ovarian Reserve","enrollment":300},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT02392429","phase":"PHASE2","title":"FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-04-20","conditions":"Acute Myeloid Leukemia","enrollment":87},{"nctId":"NCT02180867","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":"Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma","enrollment":140},{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT01627041","phase":"PHASE2","title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-16","conditions":"Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":178},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT07498231","phase":"NA","title":"COronoary Microcirculation Analysis NETwork","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2025-10-10","conditions":"Coronary Artery Disease, Microcirculation Resistance, Microcirculation; Biomarkers; Myocardial Ischemia","enrollment":180},{"nctId":"NCT05260528","phase":"PHASE2","title":"CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-05-03","conditions":"Acute Myeloid Leukemia","enrollment":248},{"nctId":"NCT06096844","phase":"PHASE3","title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-19","conditions":"Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8","enrollment":304},{"nctId":"NCT06788756","phase":"PHASE2, PHASE3","title":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML","status":"RECRUITING","sponsor":"Moleculin Biotech, Inc.","startDate":"2025-03-12","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":312},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07492693","phase":"PHASE2","title":"Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-10-01","conditions":"Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors","enrollment":40},{"nctId":"NCT07353671","phase":"PHASE2, PHASE3","title":"Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-01","conditions":"Radiation-induced Dermatitis","enrollment":60},{"nctId":"NCT07492628","phase":"PHASE1","title":"Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-03-02","conditions":"Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":42},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT07493421","phase":"NA","title":"To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.","status":"RECRUITING","sponsor":"Unidade Local de Saúde São João","startDate":"2026-03-01","conditions":"Pancreatic Adenocarcinoma, Peritoneal (Metastatic) Cancer","enrollment":20},{"nctId":"NCT07339774","phase":"PHASE2","title":"Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-30","conditions":"Radiotherapy-induced Oral Mucositis","enrollment":128},{"nctId":"NCT06313437","phase":"PHASE1","title":"Revumenib in Combination With 7+3 + Midostaurin in AML","status":"RECRUITING","sponsor":"Richard Stone, MD","startDate":"2024-12-06","conditions":"Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations","enrollment":22},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT07221474","phase":"PHASE2","title":"A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-12","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":180},{"nctId":"NCT07491536","phase":"NA","title":"Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis","status":"RECRUITING","sponsor":"University of Pavia","startDate":"2026-03-01","conditions":"Oral Mucositis, Chemotherapy-induced Oral Mucositis, Head and Neck Neoplasms","enrollment":50},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT02315612","phase":"PHASE1","title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"NHL, Large Cell Lymphoma, Follicular Lymphoma","enrollment":134},{"nctId":"NCT07180173","phase":"","title":"Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2007-04-01","conditions":"Oncology, Radiology","enrollment":7},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT04930237","phase":"","title":"RELISTOR's Effects on Opioid-Induced Constipation","status":"WITHDRAWN","sponsor":"Methodist Health System","startDate":"2021-07-01","conditions":"OIC","enrollment":""},{"nctId":"NCT06792786","phase":"NA","title":"A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring","status":"RECRUITING","sponsor":"The Central Hospital of Lishui City","startDate":"2024-12-10","conditions":"Esophageal Cancer, ctDNA","enrollment":30},{"nctId":"NCT02997332","phase":"PHASE1","title":"Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-03-30","conditions":"Head and Neck Cancers","enrollment":14},{"nctId":"NCT04248452","phase":"PHASE3","title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-05-26","conditions":"Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","enrollment":314},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT05780879","phase":"PHASE2","title":"A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-06-03","conditions":"Secondary Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07001748","phase":"PHASE2, PHASE3","title":"Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2025-08-19","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":148},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT05980169","phase":"NA","title":"The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Augusta University","startDate":"2023-11-29","conditions":"Gynecologic Cancer, Neuropathy;Peripheral","enrollment":80},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT04992572","phase":"EARLY_PHASE1","title":"Study Comparing Local/ MAC Anesthesia in Lumbar Decompression","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-12-01","conditions":"Lumbar Spinal Stenosis","enrollment":100},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT03551249","phase":"NA","title":"Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption","status":"COMPLETED","sponsor":"InSightec","startDate":"2019-03-26","conditions":"Glioma, Glioblastoma","enrollment":20},{"nctId":"NCT07409987","phase":"NA","title":"The Effect of Electrostimulation and Compression Applications on Neuropathy Symptoms and Quality of Life in the Management of Chemotherapy-Induced Peripheral Neuropathy in Gastrointestinal System Cancer Patients Receiving Oxaliplatin-Based Treatment","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2025-01-02","conditions":"CIPN - Chemotherapy-Induced Peripheral Neuropathy, Oxaliplatin, Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","enrollment":140},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT05397457","phase":"NA","title":"Effect of Helmet Type, Home-use Low-level Light Therapy Device for Chemotherapy-induced Alopecia","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-05-01","conditions":"Breast Cancer, Chemotherapy-induced Alopecia","enrollment":106},{"nctId":"NCT07483034","phase":"NA","title":"Receptive Music Therapy Effects on Anxiety, Depression, QoL, and EGF, IL-8, and NfL During the Breast Cancer Treatment.","status":"ENROLLING_BY_INVITATION","sponsor":"Brigita Vilc","startDate":"2024-10-01","conditions":"Breast Cancer Invasive, Chemotherapy, Breast Cancer Surgery","enrollment":90},{"nctId":"NCT07483736","phase":"PHASE3","title":"Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.","status":"NOT_YET_RECRUITING","sponsor":"Versailles Hospital","startDate":"2026-03","conditions":"C15.378","enrollment":1526},{"nctId":"NCT04415944","phase":"PHASE2","title":"Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-20","conditions":"Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III","enrollment":10},{"nctId":"NCT03173092","phase":"PHASE4","title":"A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2017-11-13","conditions":"Multiple Myeloma","enrollment":141},{"nctId":"NCT07479407","phase":"NA","title":"Effect of Pre-operative Exercise Training on Cardiorespiratory Fitness in Patients With Locally Advanced Non-small Cell Lung Cancer Undergoing Induction Chemo-immunotherapy Followed by Surgery - a Randomized Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Hôpital du Valais","startDate":"2026-04","conditions":"Locally Advanced Non-small Cell Lung Cancer (NSCLC)","enrollment":74},{"nctId":"NCT06152809","phase":"PHASE1","title":"CIML NK Cells With Venetoclax for AML","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-20","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia","enrollment":10},{"nctId":"NCT06181201","phase":"","title":"Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2024-02-19","conditions":"Cancer of Rectum","enrollment":2},{"nctId":"NCT07480382","phase":"NA","title":"Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC","status":"NOT_YET_RECRUITING","sponsor":"Hong Wu","startDate":"2026-04-01","conditions":"Initially Unresectable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07481149","phase":"PHASE3","title":"Trial of a Virtual Exercise-based Rehabilitation Program to Treat Persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-03-30","conditions":"Chemotherapy-induced Peripheral Neuropathy (CIPN)","enrollment":240},{"nctId":"NCT07478991","phase":"PHASE3","title":"Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2026-03","conditions":"Acute Myeloid Leukemia, Adult","enrollment":376},{"nctId":"NCT03987555","phase":"","title":"Paclitaxel Therapeutic Drug Monitoring in Cancer Patients","status":"SUSPENDED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-11-11","conditions":"Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":22},{"nctId":"NCT06095128","phase":"PHASE4","title":"A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-06-12","conditions":"Ulcerative Colitis","enrollment":65},{"nctId":"NCT05941741","phase":"PHASE3","title":"IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-10","conditions":"Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy","enrollment":380},{"nctId":"NCT04251949","phase":"PHASE2","title":"Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis.","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2021-03-19","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":28},{"nctId":"NCT07048249","phase":"EARLY_PHASE1","title":"Single Arm Romiplostim to Prevent CIT","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2024-01-26","conditions":"Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia","enrollment":26},{"nctId":"NCT07322263","phase":"PHASE2","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Michael A. O'Donnell","startDate":"2026-04-01","conditions":"Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma","enrollment":174},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT07476443","phase":"PHASE2, PHASE3","title":"Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2026-04-20","conditions":"Nephrotoxicity","enrollment":75},{"nctId":"NCT07362979","phase":"PHASE2","title":"Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-12","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":243},{"nctId":"NCT01612351","phase":"PHASE2","title":"Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-06","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT02998268","phase":"PHASE2","title":"Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2017-03-07","conditions":"Esophageal Adenocarcinoma","enrollment":42},{"nctId":"NCT07459296","phase":"PHASE3","title":"Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-03-05","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":266},{"nctId":"NCT02173756","phase":"PHASE3","title":"Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","startDate":"2014-06","conditions":"Cancer","enrollment":25},{"nctId":"NCT06405542","phase":"PHASE1","title":"Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-04-25","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":40},{"nctId":"NCT04499053","phase":"PHASE2","title":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2020-12-09","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":18},{"nctId":"NCT03842982","phase":"PHASE3","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-05-03","conditions":"Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma","enrollment":362},{"nctId":"NCT07286149","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":"Lung Neoplasm Malignant","enrollment":190},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT04001829","phase":"PHASE2","title":"Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-08-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":249},{"nctId":"NCT06861010","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-03-01","conditions":"Pancreatic Diseases","enrollment":44}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ACUTE MYELOID LEUKAEMIA"},{"count":1,"reaction":"ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE"},{"count":1,"reaction":"CLOSTRIDIAL INFECTION"},{"count":1,"reaction":"DISEASE RECURRENCE"},{"count":1,"reaction":"LEUKAEMIA RECURRENT"},{"count":1,"reaction":"MYELODYSPLASTIC SYNDROME TRANSFORMATION"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"RELAPSING-REMITTING MULTIPLE SCLEROSIS"}],"_approvalHistory":[],"publicationCount":11147,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IC","Fludara","Endoxan, Cytoxan, Neosar, Procytox, Revimmune, cytophosphane","7+3","Ara-C"],"phase":"phase_3","status":"active","brandName":"induction chemotherapy","genericName":"induction chemotherapy","companyName":"Zhejiang Cancer Hospital","companyId":"zhejiang-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Induction chemotherapy involves administering high-dose chemotherapy to kill cancer cells before a main treatment, such as surgery or radiation. Used for Treatment of various cancers, including but not limited to breast cancer, lung cancer, and lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}